ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-30 18:01 |
ABIVAX: Rapport Financier Semestriel 2022.
|
French | 999.8 KB | ||
| 2022-09-30 18:00 |
ABIVAX ANNONCE LA MISE A DISPOSITION DE SON RAPPORT FINANCIER SEMESTRIEL 2022
|
French | 140.1 KB | ||
| 2022-09-30 18:00 |
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
|
English | 7.2 KB | ||
| 2022-09-30 00:00 |
Rapport CAC sur l'information financière semestrielle
|
French | 910.4 KB | ||
| 2022-09-27 18:00 |
ABIVAX: ABSTRACT PORTANT SUR LES RESULTATS DE PHASE 2B D’OBEFAZIMOD SELECTIONNE…
|
French | 226.2 KB | ||
| 2022-09-27 18:00 |
ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PR…
|
English | 17.6 KB | ||
| 2022-09-23 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 247.8 KB | ||
| 2022-09-15 18:00 |
Abivax présente ses résultats semestriels 2022 et fait un point d’avancement su…
|
French | 344.8 KB | ||
| 2022-09-15 18:00 |
Abivax presents first-half 2022 financial results and operations update
|
English | 47.0 KB | ||
| 2022-09-15 10:16 |
Franchissement de seuils
|
French | 273.5 KB | ||
| 2022-09-15 10:14 |
Franchissements de seuils
|
French | 269.5 KB | ||
| 2022-09-13 11:49 |
Franchissement de seuils
|
French | 202.4 KB | ||
| 2022-09-12 12:58 |
Franchissement de seuil
|
French | 268.8 KB | ||
| 2022-09-06 08:00 |
Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans l…
|
French | 248.4 KB | ||
| 2022-09-06 08:00 |
Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis publ…
|
English | 20.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
